N- (1- azabicyclo(2.2.2)oct- 3- yl)furo(2,3- c)pyridine- 5- carboxamide

an alpha7 nicotinic acetylcholine receptor agonist that might be useful in treating schizophrenia; structure in first source

Also Known As:

PHA 543,613; PHA 543613; PHA-543,613; PHA-543613; PHA543613

Networked: 21 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Bridged-Ring Heterocyclic Compounds
  - Quinuclidines: 20
    - N-(1-azabicyclo(2.2.2)oct-3-yl)furo(2,3-c)pyridine-5-carboxamide: 21
  - Heterocyclic Bridged Bicyclo Compounds
    - N-(1-azabicyclo(2.2.2)oct-3-yl)furo(2,3-c)pyridine-5-carboxamide: 21

Experts

1.	Bodard, Sylvie: 3 articles (06/2021 - 01/2015)
2.	Chalon, Sylvie: 3 articles (06/2021 - 01/2015)
3.	Gu, Xiaoping: 3 articles (01/2019 - 01/2015)
4.	Liu, Yue: 3 articles (01/2019 - 01/2015)
5.	Ma, Zhengliang: 3 articles (01/2019 - 01/2015)
6.	Zhang, Wei: 3 articles (01/2019 - 01/2015)
7.	Böhm, Markus: 2 articles (01/2022 - 12/2020)
8.	Stegemann, Agatha: 2 articles (01/2022 - 12/2020)
9.	Steinbrink, Kerstin: 2 articles (01/2022 - 12/2020)
10.	Bruszt, Nóra: 2 articles (11/2021 - 02/2015)

Related Diseases

1.	Memory Disorders (Memory Loss) 01/01/2023 - "For the first time, we systematically reveal the mechanisms by which PHA-543613 improves memory deficits at different levels. " 01/01/2017 - "PHA-543613 also improved long-term neurobehavioral (sensorimotor, learning, and memory) deficits and ameliorated brain atrophy after ICH. " 02/01/2015 - "However, PHA-543613 had lower efficacy in the MK-801 induced transient amnesia model, as the pharmacologically induced memory deficit was only partially reversed and an inverted U-shaped dose-response was found. " 01/01/2023 - "Alpha7 nicotinic acetylcholine receptor agonist PHA-543613 improves memory deficits in presenilin 1 and presenilin 2 conditional double knockout mice."
2.	Atrophy 01/01/2017 - "PHA-543613 also improved long-term neurobehavioral (sensorimotor, learning, and memory) deficits and ameliorated brain atrophy after ICH. "
3.	Hyperalgesia 01/01/2017 - "In another experiment, we found that intrathecal injection of PHA-543613, a selective α7 nAchR agonist, attenuated the SPS-evoked allodynia in a dose dependent manner. " 01/01/2017 - "Taken together, the present study showed that spinal activation of α7 nAChR by PHA-543613 attenuated mechanical allodynia induced by PTSD-like stress, and the suppression of spinal glial activation may underlie this anti-hyperalgesic effect. " 01/01/2015 - "The present study investigated the effects of α7-nAChRs selective agonists PHA-543613 and type II positive allosteric modulators (PAMs) PNU-120596 in remifentanil induced postoperative hyperalgesia. "
4.	Parkinson Disease (Parkinson's Disease) 06/01/2021 - "In this context, the aim of the present study was to assess the effects of the concomitant administration of N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-furo[2,3-c]pyridine-5-carboxamide (PHA) 543613 as an a7-nAChR agonist and 2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate (PRE)-084 as a s1-R agonist in a well-characterized 6-hydroxydopamine rat model of Parkinson's disease. " 01/01/2015 - "Assessment of the Protection of Dopaminergic Neurons by an α7 Nicotinic Receptor Agonist, PHA 543613 Using [(18)F]LBT-999 in a Parkinson's Disease Rat Model."
5.	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/01/2017 - "Taken together, the present study showed that spinal activation of α7 nAChR by PHA-543613 attenuated mechanical allodynia induced by PTSD-like stress, and the suppression of spinal glial activation may underlie this anti-hyperalgesic effect. "

Related Drugs and Biologics

1.	Oxidopamine (6 Hydroxydopamine)
2.	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
3.	1- (5- chloro- 2,4- dimethoxyphenyl)- 3- (5- methylisoxazol- 3- yl)urea
4.	Nootropic Agents (Nootropics)
5.	Dizocilpine Maleate (Dizocilpine)
6.	Cholinergic Agents (Cholinergics)
7.	Scopolamine (Hyoscine)
8.	Remifentanil (Ultiva)
9.	pyridine
10.	alpha7 Nicotinic Acetylcholine Receptor

Related Therapies and Procedures

1.	Intraperitoneal Injections
2.	Perioperative Period
3.	Spinal Injections
4.	Injections